scholarly journals Non‑invasive prostate cancer detection by measuring expression level of miR-21 and miR-214 in urine

2020 ◽  
Author(s):  
Alireza Emamvirdizadeh ◽  
Faranak Jamshidian ◽  
Mehrdad Hashemi ◽  
Saghi Nooraei ◽  
Maliheh Entezari
Keyword(s):  
Prostate Cancer ◽  
Sensitivity And Specificity ◽  
Specific Antigen ◽  
High Sensitivity ◽  
Expression Level ◽  
Control Group ◽  
Non Invasive ◽  
Invasive Method ◽  
Detect Prostate Cancer ◽  
Group A

Abstract Background: Prostate cancer is the most prevalent cancer among men worldwide. Diagnosis in this cancer is primarily done using aggressive methods, such as biopsy. Laboratory methods, such as measurement of prostate specific antigen (PSA) in the blood, do not have high sensitivity and specificity. MicroRNAs, a group of diagnostic biomarkers, can be used to diagnose diseases such as cancer. MicroRNA is small, non-coding, single-stranded RNA with a length of 21-23 nucleotides. The present study was undertaken to investigate changes in the expression level of miR-21 and miR-214 in the urine to detect prostate cancer. Methods: Testing was done on 70 urine samples from prostate cancer patients (32 metastatic and 38 non-metastatic) and 30 from healthy individuals with negative biopsy reports as the control group. Changes in the expression level of miR-21 and miR-214 in the urine were investigated by using qRT-PCR. Results: miR-21 showed a significant increase in expression (p = 0.003) and miR-214 showed a significant decrease in expression (p = 0.000) over the results of the control group. The specificity, sensitivity and AUC for combined panels of both microRNAs were 100%, 72.14% and 0.721 and for PSA were 63.33%, 61.43% and 0.620, respectively. Conclusions: The results show that miR-21 and miR-214 show significant changes in expression in patients with prostate cancer compared to the control group. A combined panel of miR-21 and miR-214 can be used as a non-invasive method for detecting prostate cancer with higher sensitivity and specificity than the PSA test.

scholarly journals Non-invasive Prostate Cancer Detection by Measuring Expression Level of miR-21 and miR-214 in Urine

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Alireza Emamvirdizadeh ◽  
Faranak Jamshidian ◽  
Maliheh Entezari ◽  
Saghi Nooraei ◽  
Mehrdad Hashemi
Keyword(s):  
Prostate Cancer ◽  
Sensitivity And Specificity ◽  
Healthy Subjects ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
High Sensitivity ◽  
Expression Level ◽  
Control Group ◽  
Non Invasive ◽  
Invasive Method

Background: Prostate cancer is the most prevalent cancer among men worldwide. Diagnosis in this cancer is primarily done, using aggressive methods such as biopsy. Laboratory methods, such as the measurement of prostate-specific antigen (PSA) in the blood, do not have high sensitivity and specificity. MicroRNAs (miRNAs), a group of diagnostic biomarkers, can diagnose diseases such as cancer. MicroRNA (miRNA) is a small, non-coding, single-stranded RNA with a length of 21 to 23 nucleotides. Objectives: This study was designed to investigate the changes in the expression level of miR-21 and miR-214 in the urine of patients with prostate cancer compared with healthy controls. Methods: A total of 70 urine samples from prostate cancer patients (32 metastatic and 38 non-metastatic) and 30 from healthy subjects with negative biopsy reports were collected. The expression level of miR-21 and miR-214 in the urine were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Results: miR-21 showed a significant increase in expression (P = 0.003) and miR-214 showed a significant decrease in expression (P = 0.000) compared with the control group. The specificity, sensitivity, and area under the curve (AUC) were 100, 72.14, and 0.721% for combined panels of miR-21 and miR-214 and 63.33, 61.43, and 0.620%, respectively, for PSA. Conclusions: miR-21 and miR-214 showed significant change in expression in patients with prostate cancer compared with healthy subjects. It is hoped that, with further research, a combined panel of miR-21 and miR-214 can be used as a non-invasive method for detecting prostate cancer with higher sensitivity and specificity than the PSA test.

DIAGNOSING HIRSCHSPRUNG DISEASE IN CHILDREN: A MULTICENTER RESEARCH TRIAL

2021 ◽  
Vol 100 (2) ◽  
pp. 226-235
Author(s):  
D.A. Morozov ◽  
◽  
E.S. Pimenova ◽  
I.V. Poddoubnyi ◽  
M.Y. Kozlov ◽  
...  
Keyword(s):  
Anorectal Manometry ◽  
Diagnostic Errors ◽  
Hirschsprung Disease ◽  
High Sensitivity ◽  
Intestinal Wall ◽  
Non Invasive ◽  
Invasive Method ◽  
Group A ◽  
Medical Teams ◽  
Spearman’S Correlation

Hirschsprung disease (HD) is a congenital absence of nerve cells (ganglions) in a segment of the intestinal wall, leading to its obstruction. Diagnosis of BG in children is a labor-intensive process, on which surgical treatment tactics depend. The concentration of patients in large surgical centers with equipped diagnostic departments makes it possible to develop the most adequate examination plan while minimizing the risk of diagnostic errors. The aim of the study was to analyze methods for diagnosis of HD in children; a retrospective analysis of the records of patients hospitalized in three medical organizations in Moscow (n=201) in 2017–2019 was carried out. The first group – children with confirmed diagnosis (n=152), the second group – patients with suspicion of BG with unsatisfactory results of previous operative treatment, postoperative complications (n=49). Results: in the 1st group, irrigography was performed before hospitalization in 118 patients (77,6%). In the hospitals, irrigography was performed (repeated) for 109 (71,7%) children. 25 (16,4%) patients showed discrepancies in interpretation of the results. Thus, irrigography was applied to all patients. Intestine biopsy before hospitalization was performed in 79 patients (52%), in the hospitals – performed/repeated in 50 patients (32,9%). There were discrepancies in the interpretation of histological findings in 8 patients (18,6 per cent). Thus, in the diagnosis of HD in children, biopsies were used (before hospitalization and/or during hospitalization) in 89 patients (58,6%). Anorectal manometry was performed to 3 (2%) children. In the 2nd group a histological examination was performed (before and during hospitalization) in 41 patients (84%), anorectal manometry – in 15 patients (31%), irrigography – in all children. Correlation analysis did not reveal any relationship between the HD variant and manifestation symptoms (Spearman's correlation coefficient was –0,232 at p<0,05. Conclusion: all medical teams began examining children with suspected HD with irrigography. Various intestinal biopsies were performed in 58,6% of cases. Anorectal manometry is currently practically not used in the diagnosis of HD in children, although it is a promising non-invasive method with high sensitivity and specificity.

scholarly journals Voided urine test to diagnose prostate cancer: Preliminary report

CytoJournal ◽  
2021 ◽  
Vol 18 ◽  
pp. 26
Author(s):  
R.B. Nerli ◽  
Shridhar C. Ghagane ◽  
Saziya R. Bidi ◽  
Madhukar L. Thakur ◽  
Leonard Gomella
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Control Group ◽  
Study Group ◽  
Elderly Male ◽  
Non Invasive ◽  
Diagnose Prostate Cancer ◽  
Preliminary Study ◽  
Histopathological Studies ◽  
Vasoactive Intestinal Peptide Receptor

Objectives: Prostate cancer (PCa) is a common malignancy affecting elderly male. At present, PCa is estimated using serum prostate-specific antigen (PSA). Prostate biopsy remains the gold standard to confirm the diagnosis of PCa. In this preliminary study, we have assessed the feasibility of detecting PCa using voided urine by targeting the genomic vasoactive intestinal peptide receptor (VPAC) expressed on malignant PCa cells. Material and Methods: Patients ≥40 years old, with no lower urinary tract symptoms (LUTS) and serum PSA levels of <1.6 ng/mL formed the control group and patients ≥40 years old, with LUTS and serum PSA >2.6 ng/ mL formed the study group. Patients were advised to give the first 50 mL of voided urine sample for the detection of malignant markers by targeting the VPAC. The results of histopathological studies were then compared to the results of urine biomarker. Results: The study revealed absence of malignant markers in 75 patients (control group). In the study group, all the 33 patients with adenocarcinoma were positive for malignant markers in the biomarker study and absence of malignant markers in the 32 patients with benign histology. The results of the biomarker studies and histopathology were consistent with each other. Conclusion: This preliminary study validates our belief that patients with PCa do shed malignant cells in the urine which can be identified by targeting the VPAC. The investigation is easy and our data appear to be highly encouraging and further serve as a simple, reliable, and a non-invasive tool in the detection of PCa.

scholarly journals Prostate-Specific antigen value and micro RNAs as potential diagnostic biomarkers for prostate cancer

2021 ◽  
Vol 8 (2) ◽  
pp. 107-113
Author(s):  
Aydemir Asdemir ◽  
Sevgi Durna Dastan ◽  
Esat Korgali ◽  
Tugba Yildiz Asdemir ◽  
Huseyin Saygin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Micro Rna ◽  
Control Group ◽  
Diagnostic Biomarkers ◽  
Expression Levels ◽  
Non Invasive ◽  
Cancer Group ◽  
Micro Rnas

Objective: It is necessary to provide PSA alternatives or methods that can be used in conjunction with PSA to regress complications rising from negative biopsies and to increase diagnostic value. Patients and Methods: The study is consisting of 59 men as the sample group. Blood samples from the individuals are grouped as prostate cancer and BPH (benign prostatic hyperplasia) groups. 27 prostate cancer patients whom some of them also operated are assembled in the patients group and the other 32 individuals are grouped as BPH group. Micro RNA expression levels evaluated by RT-PCR. Results: Prostate cancer group when compared with the control group, it is observed that expression levels of miRNA-221 and miRNA-432 increased while expression levels of miRNA-17-5p, miRNA-30c, miRNA-107, miRNA-141, miRNA-145, miRNA-181a-2, miRNA-331-3p, miRNA-574-3p decreased and expression levels of miRNA-21 and miRNA-375 are quite similar between the groups. Conclusion: The prospect of strong and sensitive serum miRNA expression levels in prostate cancer cases which are easily detectable by non-invasive methods as biomarkers is a promising field of study. Nevertheless, it is currently necessary to work in conjunction with both tissue and serum to enhance both sensitivity and specificity of miRNAs as biomarkers. As such, expression levels of the same miRNAs in tissue and serum provide different expression values which in turn make it difficult to indicate a common biomarker.

scholarly journals Technetium-99m-MIBI-SPECT for prostate cancer diagnosis

2020 ◽  
pp. 20-28
Author(s):  
M. Kuru ◽  
Z. Talat ◽  
M. S. Sağer ◽  
Ç. Demirdağ
Keyword(s):  
Prostate Cancer ◽  
Sensitivity And Specificity ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Emission Computed Tomography ◽  
Prostate Cancer Diagnosis ◽  
Technetium 99M ◽  
Non Invasive ◽  
Invasive Method ◽  
Mibi Spect

The gold standard method for prostate cancer diagnosis is a transrectal ultrasonography-guided prostate biopsy. The detection rate of prostate cancer using the biopsy is approximately 25-30%. A non-invasive method Technetium-99m methoxy-isobutyl-isonitrile single-photon emission computed tomography (technetium-99m-MIBI-SPECT) could be used in prostate cancer detected. The study aimed to try to show that Tc99m-MIBI-SPECT, which is performed as a non-invasive method before biopsy in patients with prostate biopsy indication, may prevent unnecessary biopsy among these patients. Methods. Fifty-six patients who were admitted to our clinic for any lower urinary tract symptoms or routine control and who had a digital rectal examination or PSA value indication for prostate biopsy were included in this retrospective study. Technetium-99m-MIBI-SPECT our patients before the biopsy was performed, radiopharmaceutical uptake by the intensity and localization of the prostate was detected. Technetium-99m-MIBI-SPECT localization and intensity of involvement by prostate biopsy results were evaluated by nuclear medicine specialists. Results. The patients’ age and PSA level were 62.8 (31-78) years and 11.3 (2.5-100) ng/ml, respectively. Prostate cancer was detected in 27/56  (48.2%) patients. The suspicious diagnosis in technetium-99m-MIBI-SPECT images was observed in 36/56 (64.3%) patients, but prostate cancer was detected in 20 of them only. The sensitivity and specificity of technetium-99m-MIBI-SPECT were 74% and 45%, respectively. The positive and negative predictive values were 55% and  45% respectively. The diagnostic value of technetium-99m-MIBI-SPECT methods was considered as 58%. Conclusıon: The technetium-99m-MIBI-SPECT method in this study had low sensitivity and specificity for prostate cancer diagnosis. Therefore, we came to the conclusion that technetium-99m-MIBI-SPECT cannot be an alternative diagnostic method.

1097: High Sensitivity and Specificity of the High Molecular Isoform of Tenascin-C to Detect Prostate Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 289-289
Author(s):  
Heiko Wunderlich ◽  
Kathrin Katenkamp ◽  
Alexander Berndt ◽  
Jörg Schubert ◽  
Hartwig Kosmehl
Keyword(s):  
Prostate Cancer ◽  
Sensitivity And Specificity ◽  
High Sensitivity ◽  
Tenascin C ◽  
Detect Prostate Cancer

scholarly journals Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection

2021 ◽  
Vol 10 ◽  
Author(s):  
Marina Y. Zemskova ◽  
Maria V. Marinets ◽  
Andrey V. Sivkov ◽  
Julia V. Pavlova ◽  
Andrey N. Shibaev ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urine Analysis ◽  
Specific Antigen ◽  
High Specificity ◽  
Control Group ◽  
Prostate Hyperplasia ◽  
Non Invasive ◽  
Diagnostic Potential ◽  
Noninvasive Biomarker ◽  
Benign Prostate

Prostate cancer (PCa) diagnosis based on patient urine analysis provides non-invasive and promising method as compared to biopsy and a prostate-specific antigen (PSA) test. This study was conceived to investigate whether Integrin alpha V (ITGAV) protein is present in urine and assess the urinary ITGAV diagnostic potential for PCa. Materials and Methods: Urinary ITGAV expression was determined by Western blot analysis and quantified by ELISA in urine from men with PCa (n = 47), benign prostate hyperplasia (n = 42) and age-matched controls (n = 22). Results: The level of ITGAV protein was significantly lower in PCa urine samples as compared to those in the control group (p &lt; 0.00001). The decrease of ITGAV in urine was highly predictive of PCa with 91.5% sensitivity, 91.4% specificity, 0.93 area under the ROC curve, and its specificity was better than that of serum PSA. Conclusion: Urinary ITGAV provides a novel noninvasive biomarker with high specificity.

scholarly journals Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3373
Author(s):  
Milena Matuszczak ◽  
Jack A. Schalken ◽  
Maciej Salagierski
Keyword(s):  
Prostate Cancer ◽  
Liquid Biopsy ◽  
Current Knowledge ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Cost Effective ◽  
Non Invasive ◽  
Diagnosis And Prognosis

Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA) level in the blood serum. PSA is a marker produced by prostate cells, not just cancer cells. Therefore, an elevated PSA level may be associated with other symptoms such as benign prostatic hyperplasia or inflammation of the prostate gland. Due to this marker’s low specificity, a common problem is overdiagnosis, which leads to unnecessary biopsies and overtreatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, there is no doubt that the improvement of the current procedure by applying effective, sensitive and specific markers is an urgent need. Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice.

scholarly journals Clinical diagnosis of prostate cancer using digital rectal examination and prostate-specific antigen tests: a systematic review and meta-analysis of sensitivity and specificity

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Nelson C. Okpua ◽  
Simon I. Okekpa ◽  
Stanley Njaka ◽  
Augusta N. Emeh
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Sensitivity And Specificity ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Antigen Test ◽  
Rectal Examination ◽  
Prostate Specific Antigen Test ◽  
Prostate Cancers ◽  
Antigen Tests

Abstract Background Being diagnosed with cancer, irrespective of type initiates a serious psychological concern. The increasing rate of detection of indolent prostate cancers is a source of worry to public health. Digital rectal examination and prostate-specific antigen tests are the commonly used prostate cancer screening tests. Understanding the diagnostic accuracies of these tests may provide clearer pictures of their characteristics and values in prostate cancer diagnosis. This review compared the sensitivities and specificities of digital rectal examination and prostate-specific antigen test in detection of clinically important prostate cancers using studies from wider population. Main body We conducted literature search in PubMed, Medline, Science Direct, Wiley Online, CINAHL, Scopus, AJOL and Google Scholar, using key words and Boolean operators. Studies comparing the sensitivity and specificity of digital rectal examination and prostate-specific antigen tests in men 40 years and above, using biopsy as reference standard were retrieved. Data were extracted and analysed using Review manager (RevMan 5.3) statistical software. The overall quality of the studies was good, and heterogeneity was observed across the studies. The result comparatively shows that prostate-specific antigen test has higher sensitivity (P < 0.00001, RR 0.74, CI 0.67–0.83) and specificity (P < 0.00001, RR 1.81, CI 1.54–2.12) in the detection of prostate cancers than digital rectal examination. Conclusion Prostate-specific antigen test has higher sensitivity and specificity in detecting prostate cancers from men of multiple ethnic origins. However, combination of prostate-specific antigen test and standardized digital rectal examination procedure, along with patients history, may improve the accuracy and minimize over-diagnoses of indolent prostate cancers.

scholarly journals Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Xavier Ruiz-Plazas ◽  
Esther Rodríguez-Gallego ◽  
Marta Alves ◽  
Antonio Altuna-Coy ◽  
Javier Lozano-Bartolomé ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Biochemistry ◽  
Specific Antigen ◽  
Total Serum ◽  
Mrna Levels ◽  
Biomarker Panel ◽  
Non Invasive ◽  
Clinical Biomarkers ◽  
Cancer Aggressiveness ◽  
Aggressive Tumors

Abstract Background Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment of PCa aggressiveness. Methods We collected biofluid samples (plasma/serum/semen/post-prostatic massage urine) from 98 patients that had undergone radical prostatectomy. Clinical biochemistry was performed and several cytokines/chemokines including soluble(s) TWEAK, sFn14, sCD163, sCXCL5 and sCCL7 were quantified by ELISA in selected biofluids. Also, the expression of KLK2, KLK3, Fn14, CD163, CXCR2 and CCR3 was quantified by real-time PCR in semen cell sediment. Univariate, logistic regression, and receiver operating characteristic (ROC) analyses were used to assess the predictive ability of the selected biomarker panel in conjunction with clinical and metabolic variables for the evaluation of PCa aggressiveness. Results Total serum levels of prostate-specific antigen (PSA), semen levels of sTWEAK, fasting glycemia and mRNA levels of Fn14, KLK2, CXCR2 and CCR3 in semen cell sediment constituted a panel of markers that was significantly different between patients with less aggressive tumors [International Society of Urological Pathology (ISUP) grade I and II] and those with more aggressive tumors (ISUP grade III, IV and V). ROC curve analysis showed that this panel could be used to correctly classify tumor aggressiveness in 90.9% of patients. Area under the curve (AUC) analysis revealed that this combination was more accurate [AUC = 0.913 95% confidence interval (CI) 0.782–1] than a classical non-invasive selected clinical panel comprising age, tumor clinical stage (T-classification) and total serum PSA (AUC = 0.721 95% CI 0.613–0.830). Conclusions TWEAK/Fn14 axis in combination with a selected non-invasive biomarker panel, including conventional clinical biochemistry, can improve the predictive power of serum PSA levels and could be used to classify PCa aggressiveness.

Sign in / Sign up

Export Citation Format

Share Document